Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01712217 · ClinicalTrials.gov registry record · Phase 1
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Phase 1 study, sponsored by Astex Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 220
- Enrollment target
NCT01712217 is a Phase 1 study that has completed, run by Astex Pharmaceuticals. The registered enrollment target is 220 participants.
The verdict
NCT01712217, a Phase 1 study, has completed, sponsored by Astex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 220 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate safety and efficacy of AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer.
Interventions
- DRUG Crizotinib
- DRUG AT13387
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2012-10 |
| Est. Completion | 2017-05-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01712217
The ClinicalTrials.gov registry entry for NCT01712217 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astex Pharmaceuticals, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Crizotinib is the first listed.
NCT01712217 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01712217 about?
NCT01712217 is a clinical study titled "A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib". The purpose of the study is to evaluate safety and efficacy of AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer.
What is the current status of trial NCT01712217?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 220 participants. The study started on 2012-10. Estimated completion is 2017-05-16.
What interventions are being tested in trial NCT01712217?
The interventions under investigation include: Crizotinib (DRUG), AT13387 (DRUG).
Who is sponsoring clinical trial NCT01712217?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.